Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H.

Blood. 2009 Apr 30;113(18):4331-40. doi: 10.1182/blood-2008-09-178350.


Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H.

Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296.


Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.

Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C, Perry T, Chau H, Belch A, Pilarski L, Reiman T.

Leuk Lymphoma. 2008 Mar;49(3):559-69. doi: 10.1080/10428190701824544.


The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T.

Br J Haematol. 2008 Feb;140(3):295-302.


Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.

Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjärn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML.

Leukemia. 2013 Mar;27(3):560-8. doi: 10.1038/leu.2012.256.


Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition.

Herz C, Schlürmann F, Batarello D, Fichter CD, Schöpflin A, Münch C, Hauschke D, Werner M, Lassmann S.

Mol Carcinog. 2012 Sep;51(9):696-710. doi: 10.1002/mc.20823.


Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.

Glant TT, Besenyei T, Kádár A, Kurkó J, Tryniszewska B, Gál J, Soós G, Szekanecz Z, Hoffmann G, Block JA, Katz RS, Mikecz K, Rauch TA.

Arthritis Rheum. 2013 Jul;65(7):1725-35. doi: 10.1002/art.37986.


Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.

Borges KS, Castro-Gamero AM, Moreno DA, da Silva Silveira V, Brassesco MS, de Paula Queiroz RG, de Oliveira HF, Carlotti CG Jr, Scrideli CA, Tone LG.

J Cancer Res Clin Oncol. 2012 Mar;138(3):405-14. doi: 10.1007/s00432-011-1111-0.


Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Bolomsky A, Hose D, Schreder M, Seckinger A, Lipp S, Klein B, Heintel D, Ludwig H, Zojer N.

J Hematol Oncol. 2015 Feb 8;8:10. doi: 10.1186/s13045-014-0105-1.


Targeting aurora kinases as therapy in multiple myeloma.

Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A.

Blood. 2007 May 1;109(9):3915-21.


The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition.

Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R.

Blood. 2008 Feb 1;111(3):1603-9.


In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS.

Br J Haematol. 2009 Dec;147(5):672-6. doi: 10.1111/j.1365-2141.2009.07891.x.


Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.

Inamdar KV, O'Brien S, Sen S, Keating M, Nguyen MH, Wang X, Fernandez M, Thomazy V, Medeiros LJ, Bueso-Ramos CE.

Mod Pathol. 2008 Dec;21(12):1428-35. doi: 10.1038/modpathol.2008.173.


Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U.

Blood. 2010 Sep 2;116(9):1498-505. doi: 10.1182/blood-2009-11-251074.


A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC.

Blood. 2010 Jun 24;115(25):5202-13. doi: 10.1182/blood-2009-12-259523.


The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

Hose D, Seckinger A, Jauch A, Rème T, Moreaux J, Bertsch U, Neben K, Klein B, Goldschmidt H.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:84-9.


Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL.

Head Neck. 2009 May;31(5):625-34. doi: 10.1002/hed.21007.


Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, Foreman NK, Liu AK, Vibhakar R.

J Neurooncol. 2012 May;107(3):517-26. doi: 10.1007/s11060-011-0795-y.


Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D.

Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257.

Supplemental Content

Support Center